Trials / Unknown
UnknownNCT05127096
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- CellMax Life · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | FirstSight blood test | FirstSight blood test for colorectal cancer screening |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2022-09-30
- Completion
- 2022-12-30
- First posted
- 2021-11-19
- Last updated
- 2021-11-19
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05127096. Inclusion in this directory is not an endorsement.